NASDAQ:IMRN

Immuron Q2 2026 Earnings Results & Report

Immuron logo
$0.90 +0.05 (+5.86%)
Closing price 11/20/2026 03:49 PM Eastern
Extended Trading
$0.83 -0.07 (-7.54%)
As of 11/20/2026 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immuron reported Q2 2026 earnings on February 25, 2026. The company reported EPS of -$0.0950, while revenue was $1.40 million.

Earnings Announcement Details

Quarter
Q2 2026
Time
Before Market Opens

Immuron EPS Results

Actual EPS
-$0.0950
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Immuron Revenue Results

Actual Revenue
$1.40 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Immuron Q2 2026 Earnings FAQ

Immuron (NASDAQ:IMRN) reported earnings of -$0.0950 per share for Q2 2026. The report was announced on Wednesday, February 25, 2026.

Immuron reported revenue of $1.40 million for Q2 2026.

Immuron Earnings Headlines

Whoops! I wasn’t supposed to share this with you yet
Traders have paid as much as $500 for technology like this. Thomas Wood of Base Camp Trading is offering his proprietary Snapback Indicator for just $7. There is no subscription and no recurring charge, and it's yours for life. The indicator is designed to help identify potential market turning points, showing when it may be time to buy, sell, or go short.tc pixel
See More Immuron Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immuron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuron and other key companies, straight to your email.

About Immuron

Immuron (NASDAQ:IMRN) Limited is an Australian biopharmaceutical company that develops and commercializes oral antibody-based products. Its approach uses targeted antibodies intended to bind pathogens or other biological targets in the gastrointestinal tract.

The company’s principal commercial product is Travelan, an oral product designed to help prevent travelers’ diarrhea. Immuron also develops investigational therapies for infectious and inflammatory conditions, including candidates focused on Clostridioides difficile infection and other gastrointestinal diseases.

Based in Melbourne, Immuron serves customers in Australia and other markets through sales and distribution arrangements. Its activities span commercializing oral health products and advancing its therapeutic candidates through clinical development.

View Immuron Profile